Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide + AAP vs AAP in Chemotherapy-naive mCRPC
NCT02257736Phase 3Active, not recruiting
- Sponsor
- Aragon Pharmaceuticals
- Start
- Nov 2014
- Primary completion
- Mar 2018
- Modality
- Orthosteric Ligands
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Group 1: AAP and apalutamide with Group 2: AAP and Placebo (2 arms). Primary endpoint: Radiographic Progression-free Survival. Started Nov 2014; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02257736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257736.